FOX - Resverlogix: Dedicated to Improving the Lives of Patients with Chronic Illnesses
Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses o …
The future of drug development
Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound (apabetalone) and evaluating its therapeutic potential in the treatment of vascular disease and COVID-19.
Resverlogix Corp. (“Resverlogix” or the “Company”), founded in 2001 by Donald McCaffrey and Norman Wong, is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. We provide novel science, clinical and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups. In 2005, Resverlogix commenced trading on the TSX under the symbol RVX.
For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.
Latest Articles
.png)
Hot Companies
You might also like
Southern Silver: Is Cerro Las Minitas Emerging as a Major Silver Project?
Southern Silver is advancing its flagship Cerro Las Minitas silver-lead-zinc project in Mexico, which management describes as one of the larger, higher-grade silver-based projects globally.
CEO Clip - Southern Silver: Can a Growing Silver Resource Support a Major Underground Mine in Mexico?
Southern Silver is advancing the Cerro Las Minitas silver-lead-zinc project in Durango, Mexico, where additional drilling is being incorporated into an updated mineral resource estimate and Preliminary Economic Assessment.
